5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study

Stacy D'Andre, Daniel J. Sargent, Stephen S. Cha, Thomas R. Buroker, John W. Kugler, Richard M. Goldberg, Michael J. O'Connell, Michael A. Poon

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Although 5-fluorouracil (5-FU) - based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients. To compare toxicity, dose intensity, response rate, time to tumor progression, and overall survival for older and younger patients, we conducted a pooled analysis of 1748 patients, divided into 4 quartile-based age groups, from 4 North Central Cancer Treatment Group trials testing 5-FU with or without leucovorin for advanced CRC. Patients aged > 65 years had modestly higher rates of severe toxicity (grade ≥ 3) overall (53% vs. 46%) and higher rates of diarrhea (21% vs. 16%), stomatitis (17% vs. 13%), and infection (4% vs. 2%). Toxicity rates were similar between patients aged 66-70 years and patients aged > 70 years. The response rate did not differ by age group (2-sided; P = 0.90); it was significantly lower for patients with higher performance status scores (30% for score of 0/1; 17% for 2/3; 2-sided; P = 0.001). Performance status, not age, was predictive of time to tumor progression and overall survival. The older patients with CRC treated with 5-FU have modestly higher rates of severe toxicity, mainly diarrhea and stomatitis. Supportive measures to control diarrhea and stomatitis may be particularly important in elderly patients. Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalClinical Colorectal Cancer
Volume4
Issue number5
StatePublished - 2005

Fingerprint

Fluorouracil
Colorectal Neoplasms
Drug Therapy
Neoplasms
Stomatitis
Therapeutics
Diarrhea
Survival
Age Groups
Leucovorin

Keywords

  • Age
  • Clinical trial
  • Drug toxicity
  • Pooled analysis
  • Survival
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

D'Andre, S., Sargent, D. J., Cha, S. S., Buroker, T. R., Kugler, J. W., Goldberg, R. M., ... Poon, M. A. (2005). 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study. Clinical Colorectal Cancer, 4(5), 325-331.

5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients : A North Central Cancer Treatment Group study. / D'Andre, Stacy; Sargent, Daniel J.; Cha, Stephen S.; Buroker, Thomas R.; Kugler, John W.; Goldberg, Richard M.; O'Connell, Michael J.; Poon, Michael A.

In: Clinical Colorectal Cancer, Vol. 4, No. 5, 2005, p. 325-331.

Research output: Contribution to journalArticle

D'Andre, S, Sargent, DJ, Cha, SS, Buroker, TR, Kugler, JW, Goldberg, RM, O'Connell, MJ & Poon, MA 2005, '5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study', Clinical Colorectal Cancer, vol. 4, no. 5, pp. 325-331.
D'Andre, Stacy ; Sargent, Daniel J. ; Cha, Stephen S. ; Buroker, Thomas R. ; Kugler, John W. ; Goldberg, Richard M. ; O'Connell, Michael J. ; Poon, Michael A. / 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients : A North Central Cancer Treatment Group study. In: Clinical Colorectal Cancer. 2005 ; Vol. 4, No. 5. pp. 325-331.
@article{5b69244422e747e8ad224b8499f87d50,
title = "5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study",
abstract = "Although 5-fluorouracil (5-FU) - based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients. To compare toxicity, dose intensity, response rate, time to tumor progression, and overall survival for older and younger patients, we conducted a pooled analysis of 1748 patients, divided into 4 quartile-based age groups, from 4 North Central Cancer Treatment Group trials testing 5-FU with or without leucovorin for advanced CRC. Patients aged > 65 years had modestly higher rates of severe toxicity (grade ≥ 3) overall (53{\%} vs. 46{\%}) and higher rates of diarrhea (21{\%} vs. 16{\%}), stomatitis (17{\%} vs. 13{\%}), and infection (4{\%} vs. 2{\%}). Toxicity rates were similar between patients aged 66-70 years and patients aged > 70 years. The response rate did not differ by age group (2-sided; P = 0.90); it was significantly lower for patients with higher performance status scores (30{\%} for score of 0/1; 17{\%} for 2/3; 2-sided; P = 0.001). Performance status, not age, was predictive of time to tumor progression and overall survival. The older patients with CRC treated with 5-FU have modestly higher rates of severe toxicity, mainly diarrhea and stomatitis. Supportive measures to control diarrhea and stomatitis may be particularly important in elderly patients. Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival.",
keywords = "Age, Clinical trial, Drug toxicity, Pooled analysis, Survival, Toxicity",
author = "Stacy D'Andre and Sargent, {Daniel J.} and Cha, {Stephen S.} and Buroker, {Thomas R.} and Kugler, {John W.} and Goldberg, {Richard M.} and O'Connell, {Michael J.} and Poon, {Michael A.}",
year = "2005",
language = "English (US)",
volume = "4",
pages = "325--331",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients

T2 - A North Central Cancer Treatment Group study

AU - D'Andre, Stacy

AU - Sargent, Daniel J.

AU - Cha, Stephen S.

AU - Buroker, Thomas R.

AU - Kugler, John W.

AU - Goldberg, Richard M.

AU - O'Connell, Michael J.

AU - Poon, Michael A.

PY - 2005

Y1 - 2005

N2 - Although 5-fluorouracil (5-FU) - based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients. To compare toxicity, dose intensity, response rate, time to tumor progression, and overall survival for older and younger patients, we conducted a pooled analysis of 1748 patients, divided into 4 quartile-based age groups, from 4 North Central Cancer Treatment Group trials testing 5-FU with or without leucovorin for advanced CRC. Patients aged > 65 years had modestly higher rates of severe toxicity (grade ≥ 3) overall (53% vs. 46%) and higher rates of diarrhea (21% vs. 16%), stomatitis (17% vs. 13%), and infection (4% vs. 2%). Toxicity rates were similar between patients aged 66-70 years and patients aged > 70 years. The response rate did not differ by age group (2-sided; P = 0.90); it was significantly lower for patients with higher performance status scores (30% for score of 0/1; 17% for 2/3; 2-sided; P = 0.001). Performance status, not age, was predictive of time to tumor progression and overall survival. The older patients with CRC treated with 5-FU have modestly higher rates of severe toxicity, mainly diarrhea and stomatitis. Supportive measures to control diarrhea and stomatitis may be particularly important in elderly patients. Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival.

AB - Although 5-fluorouracil (5-FU) - based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients. To compare toxicity, dose intensity, response rate, time to tumor progression, and overall survival for older and younger patients, we conducted a pooled analysis of 1748 patients, divided into 4 quartile-based age groups, from 4 North Central Cancer Treatment Group trials testing 5-FU with or without leucovorin for advanced CRC. Patients aged > 65 years had modestly higher rates of severe toxicity (grade ≥ 3) overall (53% vs. 46%) and higher rates of diarrhea (21% vs. 16%), stomatitis (17% vs. 13%), and infection (4% vs. 2%). Toxicity rates were similar between patients aged 66-70 years and patients aged > 70 years. The response rate did not differ by age group (2-sided; P = 0.90); it was significantly lower for patients with higher performance status scores (30% for score of 0/1; 17% for 2/3; 2-sided; P = 0.001). Performance status, not age, was predictive of time to tumor progression and overall survival. The older patients with CRC treated with 5-FU have modestly higher rates of severe toxicity, mainly diarrhea and stomatitis. Supportive measures to control diarrhea and stomatitis may be particularly important in elderly patients. Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival.

KW - Age

KW - Clinical trial

KW - Drug toxicity

KW - Pooled analysis

KW - Survival

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=14644429819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644429819&partnerID=8YFLogxK

M3 - Article

C2 - 15663836

AN - SCOPUS:14644429819

VL - 4

SP - 325

EP - 331

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 5

ER -